Overview

Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy

Status:
Not yet recruiting
Trial end date:
2025-01-23
Target enrollment:
Participant gender:
Summary
The purpose of the present study is to assess the efficacy of secukinumab 300 mg s.c. (subcutaneous) compared to placebo, each in combination with standard of care, in improving signs, symptoms and physical function in participants with moderate to severe rotator cuff tendinopathy (RCT), using a randomized, double-blind, placebo controlled, parallel group design to minimize bias.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals